Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Fig. 5

The combination treatment with JNK-IN-8 and dasatinib significantly prolongs the life of BCR/ABL+ B-ALL mice. a Percentage of GFP-positive CD19+ B lymphocytes in peripheral blood (PB) from BCR/ABLp190 bone marrow transduction and transplantation mice treated with vehicle, dasatinib (2 mg/kg), JNK-IN-8 (20 mg/kg) alone, or both in combination QD, respectively, for 3 days. b Percentage of GFP-positive CD19+ B lymphocytes in PB from BCR/ABLp190 bone marrow transduction and transplantation mice treated with compounds as described in a for 8 days. c Hematoxylin and eosin staining of spleens from BCR/ABLp190 bone marrow transduction and transplantation mice treated with compounds as described in a for 10 days. Scale bars in the upper and lower panel are 200 μm and 50 μm, respectively. d Flow cytometry analysis of bone marrow cells from mice as described in C. e The Kaplan-Meier survival curves of BCR/ABLp190 bone marrow transduction and transplantation mice continuously administrated with vehicle, dasatinib (2 mg/kg), JNK-IN-8 (20 mg/kg) alone, or both drugs in combination QD for 18 days. P values were calculated by log-rank test and shown

Back to article page